Breaking News

Tonix Pharma Names Clinical Development and RA SVP

April 1, 2014

Kellerman to oversee strategy and execution of clinical programs

Donald J. Kellerman, Pharm.D. has been appointed senior vice president of Clinical Development and Regulatory Affairs at Tonix Pharmaceuticals. Dr. Kellerman will be responsible for overseeing strategy and execution of the company’s clinical programs.
 
Dr. Kellerman has more than 30 years of experience in pharmaceutical development, spanning several therapeutic areas including central nervous system, respiratory, allergy, ophthalmology and cardiovascular. Dr. Kellerman previously served as senior vice president, Clinical Development and Medical Affairs at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.), where he managed the development of MAP0004 for the treatment of migraine. Dr. Kellerman also held positions at Inspire Pharmaceuticals, Inc. (acquired by Merck), Glaxo Wellcome plc, Sepracor, Inc. (acquired by Dainippon Sumitomo Pharma Co.), Ciba-Geigy Corp., and E.R. Squibb and Sons, Inc.
 
"We welcome Don Kellerman to Tonix's executive management team as we bring our headache program into the clinic later this year," said Seth Lederman, MD, president and chief executive officer of Tonix. "His recent and successful experience shepherding a novel formulation of a decades-old agent for migraine through a registration program and a New Drug Application (NDA) submission is reflective of our business approach and will be of great value to Tonix."
 

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks